BR112018073634A2 - compostos fenólicos eletrofilicamente aprimorados para o tratamento de doenças e transtornos inflamatórios - Google Patents

compostos fenólicos eletrofilicamente aprimorados para o tratamento de doenças e transtornos inflamatórios

Info

Publication number
BR112018073634A2
BR112018073634A2 BR112018073634-1A BR112018073634A BR112018073634A2 BR 112018073634 A2 BR112018073634 A2 BR 112018073634A2 BR 112018073634 A BR112018073634 A BR 112018073634A BR 112018073634 A2 BR112018073634 A2 BR 112018073634A2
Authority
BR
Brazil
Prior art keywords
group
inflammatory diseases
treatment
disorders
phenolic compounds
Prior art date
Application number
BR112018073634-1A
Other languages
English (en)
Inventor
Lee Thompson Daryl
Original Assignee
Global Biolife Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Biolife Inc. filed Critical Global Biolife Inc.
Publication of BR112018073634A2 publication Critical patent/BR112018073634A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

um composto terapêutico tem um composto fenólico modificado de fórmula geral (i) em que pelo menos um de r, r1, r2, r3 e r4 é um grupo eletrofílico escolhido entre halogênio, aldeído, haloalcano, alceno, butirila, flurofenol, sulfonamida, flurofenol sulfóxido e os r, r1, r2, r3 e r4 restantes são cada um independentemente hidrogênio, um grupo hidroxila, um grupo alcóxi, um grupo rutinosila, um grupo carboxila, cromona, benzopirano, um grupo ramnosila, um grupo alcóxi substituído ou um grupo acilóxi substituído, em que o substituinte é escolhido de grupos hidroxila, alcóxi, arilóxi, fenila, halogênio e amido. o composto pode ser utilizado em um tratamento terapêutico de doenças e condições inflamatórias.
BR112018073634-1A 2016-05-16 2017-05-16 compostos fenólicos eletrofilicamente aprimorados para o tratamento de doenças e transtornos inflamatórios BR112018073634A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/156,021 US10123991B2 (en) 2015-05-15 2016-05-16 Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
US15/156,021 2016-05-16
PCT/US2017/032897 WO2017201042A1 (en) 2015-05-15 2017-05-16 Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders

Publications (1)

Publication Number Publication Date
BR112018073634A2 true BR112018073634A2 (pt) 2019-02-26

Family

ID=57276515

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073634-1A BR112018073634A2 (pt) 2016-05-16 2017-05-16 compostos fenólicos eletrofilicamente aprimorados para o tratamento de doenças e transtornos inflamatórios

Country Status (10)

Country Link
US (1) US10123991B2 (pt)
EP (1) EP3458160A4 (pt)
JP (2) JP2019515022A (pt)
KR (2) KR20190013830A (pt)
CN (1) CN109475757A (pt)
AU (1) AU2017268240B2 (pt)
BR (1) BR112018073634A2 (pt)
CA (1) CA3024728C (pt)
RU (1) RU2018141590A (pt)
WO (1) WO2017201042A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10123991B2 (en) 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
US10966954B2 (en) * 2016-05-16 2021-04-06 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
WO2019045677A1 (en) * 2017-08-28 2019-03-07 Global Biolife Inc. METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS
CN110003231B (zh) * 2019-04-30 2021-08-10 遵义医科大学 1，1-螺降冰片烷-吡喃并[4，3-b]色酮类化合物及其制备方法和应用
US20230132782A1 (en) * 2020-03-16 2023-05-04 Global Biolife Inc. Method and compositions for treating, preventing or limiting the occurrence of viral infection
CN113440514B (zh) * 2021-08-20 2022-09-09 中国农业科学院郑州果树研究所 含橙皮素的组合物及其制备降血糖药物的应用
US20230165831A1 (en) * 2021-11-19 2023-06-01 Impact Biolife Science, Inc. Method and composition for rendering cancer cells susceptible to treatment by targeted oncogenetic drivers

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689663A (en) 1963-08-28 1972-09-05 Merck Ag E Lowering cholesterol blood levels with flavanoids
US3453282A (en) 1965-12-27 1969-07-01 Parke Davis & Co Novel 4'-aminoethoxy-2,2,4-trialkyl-delta**3-isoflaven compounds
FR5443M (pt) 1966-04-26 1967-10-09
US4157334A (en) 1974-12-26 1979-06-05 Carlo Erba S. P. A. 6-Carboxy-flavone derivatives and process for their preparation
GB1589294A (en) 1976-09-08 1981-05-13 Inverni Della Beffa Spa Pharmaceutical compositions containing anthocyanidines
US4376781A (en) 1978-02-27 1983-03-15 Inverni Della Beffa S.P.A. Pharmaceutical compositions
US4241069A (en) 1979-09-04 1980-12-23 Miles Laboratories, Inc. 3-Methylene flavanones and 3-methylene chromanones
FR2480599A1 (fr) * 1980-04-17 1981-10-23 Oreal Utilisation de derives hydroxyles du benzaldehyde pour la coloration des fibres keratiniques, procede et composition les mettant en oeuvre
US5116954A (en) 1988-04-06 1992-05-26 Lipha, Lyonnaise Industrielle Pharmaceutique Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety
JPH0784383B2 (ja) 1991-07-23 1995-09-13 辻本化学工業株式会社 抗発癌プロモーター剤
US5399584A (en) 1992-05-05 1995-03-21 The Procter & Gamble Company Use of flavone derivatives for gastroprotection
GB9317071D0 (en) 1993-08-17 1993-09-29 Univ Strathclyde Flavonoids
ES2168392T3 (es) 1994-12-02 2002-06-16 Kao Corp Derivados de flavanonol y compuesto estimulante para la nutricion y crecimiento del cabello que los contiene.
GB9521184D0 (en) 1995-10-17 1995-12-20 Univ Strathclyde Flavonoids
WO1998027970A2 (en) 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
CA2284290A1 (en) 1997-03-20 1998-09-24 Samuel Russell Vester Nutritional supplement for cardiovascular health
US7183314B1 (en) 2000-07-21 2007-02-27 Naturon Limited Compound for treatment of anxiety and methods of preparation and use thereof
IL161765A0 (en) * 2001-11-09 2005-11-20 Proteologics Inc P85-alpha nucleic acids, polypeptides and related methods
GB0216371D0 (en) 2002-07-13 2002-08-21 Rowett Res Inst The Compounds
US6740677B2 (en) 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids
AU2006222556B2 (en) 2005-03-11 2011-09-29 Armaron Bio Pty Ltd Flavonoid compounds and uses thereof
JP2007084494A (ja) * 2005-09-22 2007-04-05 Oncorex Inc Ｐｉｍ−１活性阻害剤
US20080292607A1 (en) 2005-11-23 2008-11-27 Elizabeth Mazzio Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
US20070116779A1 (en) 2005-11-23 2007-05-24 Elizabeth Mazzio Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease
WO2008011538A2 (en) 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory
WO2008021210A2 (en) 2006-08-11 2008-02-21 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
US8022246B2 (en) 2006-10-10 2011-09-20 The Burnham Institute For Medical Research Neuroprotective compositions and methods
CN101842095B (zh) 2007-07-02 2015-06-24 于明 肿瘤治疗的配方,方法和靶目标
US8034838B2 (en) * 2008-05-29 2011-10-11 Daryl Lee Thompson Composition and method for the treatment of neurological disorders
WO2010063300A1 (en) 2008-12-03 2010-06-10 Università Degli Studi Di Torino Isogenic human cell lines comprising mutated cancer alleles and process using the cell lines
EP2241313A1 (en) * 2009-03-31 2010-10-20 Nestec S.A. Use of flavonoids to increase the bioavailability of hesperetin
US9296717B2 (en) 2009-08-19 2016-03-29 University Of The Free State Synthesis of C-3 coupled biflavonoids and C-3 coupled biflavonoid analogues
CA3023725C (en) * 2009-10-22 2021-09-14 Vizuri Health Sciences Llc Methods of producing hydrated flavonoids and use thereof in the preparation of topical compositions
US20120039796A1 (en) 2010-08-15 2012-02-16 Demetrios Markou Novel method for creating, suspending and stabilizing electronically modified oxygen derivatives, along with creating, suspending and stabilizing electronically modified reaction intermediates, in a bio compatible fluorocarbon suspension, for the purpose of inducing a cascading immune response in mammalian patients
GB201017315D0 (en) 2010-10-13 2010-11-24 Antoxis Ltd Compound
RU2014116639A (ru) 2011-09-27 2015-11-10 Вирджиния Коммонвелт Юниверсити Избирательный метаболический подход к повышению биодоступности фенилэфрина и других фенольных биологически активных веществ при пероральном приеме
CN103570694B (zh) * 2012-07-23 2017-05-03 厦门鹭佳生物科技有限公司 淫羊藿素及其衍生物的制备及其在肿瘤治疗中的应用
JP2014047173A (ja) * 2012-08-31 2014-03-17 Ezaki Glico Co Ltd ヘスペレチン代謝物を長時間血中に保つための組成物およびその製造法
CN103012347B (zh) * 2012-12-29 2015-03-11 吉首大学 尿素酶抑制剂黄酮氧肟酸类化合物及其制法和用途
US20140294788A1 (en) 2013-03-26 2014-10-02 Nestec S.A. Methods for enhancing muscle protein synthesis following concurrent training
WO2014168925A1 (en) 2013-04-08 2014-10-16 Virginia Commonwealth University Compositions to alleviate presystemic metabolism of opioids
JP6660661B2 (ja) * 2014-06-23 2020-03-11 江崎グリコ株式会社 風味改善剤及び風味改善方法
WO2016027837A1 (ja) * 2014-08-20 2016-02-25 株式会社林原 経口美容剤
US10383842B2 (en) * 2015-02-13 2019-08-20 Global Biolife Inc. Method and composition for preventing and treating viral infections
EP3132692A1 (en) 2015-03-24 2017-02-22 Biosens Croatia Compositions comprising small molecular inhibitors suitable to inhibit and stimulate signaling pathways in a manner leading to prevention of muscle atrophy
US10123991B2 (en) 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
US20190076394A1 (en) 2015-09-22 2019-03-14 Scientific Formulations, Llc Therapeutics for Malaria

Also Published As

Publication number Publication date
WO2017201042A1 (en) 2017-11-23
CA3024728A1 (en) 2017-11-23
AU2017268240A1 (en) 2018-12-06
KR20190013830A (ko) 2019-02-11
EP3458160A1 (en) 2019-03-27
EP3458160A4 (en) 2020-01-29
JP7376624B2 (ja) 2023-11-08
US10123991B2 (en) 2018-11-13
RU2018141590A3 (pt) 2020-06-17
KR20230078822A (ko) 2023-06-02
US20160331722A1 (en) 2016-11-17
CA3024728C (en) 2024-02-13
RU2018141590A (ru) 2020-06-17
JP2019515022A (ja) 2019-06-06
AU2017268240B2 (en) 2023-05-25
JP2022058792A (ja) 2022-04-12
CN109475757A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
BR112018073634A2 (pt) compostos fenólicos eletrofilicamente aprimorados para o tratamento de doenças e transtornos inflamatórios
BR112017009648A2 (pt) composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
CY1120692T1 (el) Καινοφανη παραγωγα βενζιμιδαζολης ως αναστολεις κινασων
ECSP18082774A (es) Derivados aromáticos de sulfonamida
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
BR112015027951A2 (pt) arilquinazolinas
BR112015026830A2 (pt) composto, composição farmacêutica, uso de um composto, método para profilaxia ou tratamento de um estado de doença ou condição
BR112015023349A2 (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
NO20082089L (no) Fosfatidylinositol 3-kinaseinhibitorer og deres anvendelse
BR112016000127A8 (pt) compostos bicíclicos úteis para tratar doenças causadas por retrovírus
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
CY1123477T1 (el) Παραγωγα βενζοξαζινονης για την αγωγη δερματικων νοσων
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
AR107529A1 (es) Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento
CR20150432A (es) Estra-1,3,5 (10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112018068247A2 (pt) novas junções de três vias de prna
BR112017022269A2 (pt) métodos para tratar câncer
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]